StockNews.com Initiates Coverage on Trevena (NASDAQ:TRVN)

StockNews.com began coverage on shares of Trevena (NASDAQ:TRVN) in a research note issued on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright decreased their price objective on shares of Trevena from $225.00 to $125.00 and set a “buy” rating for the company in a report on Thursday, May 16th.

Trevena Stock Down 5.2 %

Shares of NASDAQ TRVN opened at $4.00 on Wednesday. Trevena has a fifty-two week low of $3.35 and a fifty-two week high of $28.00. The firm’s 50-day simple moving average is $5.11 and its 200 day simple moving average is $9.16. The stock has a market cap of $73.36 million, a P/E ratio of -1.49 and a beta of 1.05.

Trevena (NASDAQ:TRVN) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($9.25) by $9.02. The company had revenue of $0.33 million for the quarter. On average, sell-side analysts anticipate that Trevena will post -32.25 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Trevena

A hedge fund recently bought a new stake in Trevena stock. Armistice Capital LLC acquired a new stake in shares of Trevena, Inc. (NASDAQ:TRVN) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 797,714 shares of the biopharmaceutical company’s stock, valued at approximately $576,000. Armistice Capital LLC owned approximately 4.61% of Trevena at the end of the most recent quarter. Institutional investors own 13.56% of the company’s stock.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.